المؤلفون: Chin-Lenn, L, De Boer, RH, Segelov, E, Marx, GM, Hughes, TM, McCarthy, NJ, White, SC, Foo, SS, Rutovitz, JJ, Della-Fiorentina, S, Jennens, R, Antill, YC, Tsoi, D, Cronk, MF, Lombard, JM, Kiely, BE, Chirgwin, JH, Gorelik, A, Mann, GB

Relation: Chin-Lenn, L., De Boer, R. H., Segelov, E., Marx, G. M., Hughes, T. M., McCarthy, N. J., White, S. C., Foo, S. S., Rutovitz, J. J., Della-Fiorentina, S., Jennens, R., Antill, Y. C., Tsoi, D., Cronk, M. F., Lombard, J. M., Kiely, B. E., Chirgwin, J. H., Gorelik, A. & Mann, G. B. (2018). The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 14 (6), pp.410-416. https://doi.org/10.1111/ajco.13075.; http://hdl.handle.net/11343/284567

الاتاحة: http://hdl.handle.net/11343/284567

المؤلفون: Marx GM (AUTHOR), Rutovitz JJ (AUTHOR)

المصدر: Women's Oncology Review. Jun2004, Vol. 4 Issue 2, p133-134. 2p.